Liečba pacientov s metastatickým renálnym karcinómom po liečbe tyrozínkinázovými inhibítormi // SOLEN

Onkológia 4/2019

Treatment of patients with metastatic renal cancer after treatment with tyrosine kinase inhibitors

In the last two decades, we observe significant progress in the treatment of the patients with metastatic renal cancer (mRCC). In the last years, the armamentarium of systemic therapeutic options became broader thanks to arrival of modern immunotherapy. Recommendations for the sequence of therapy result from randomized clinical trials, but real practice often depends on availability of individual treatment options. The article gives an overview of the treatment strategies in the patients with mRCC who are pretreated with VEGF-TKi. In aim to give a whole picture of mRCC treatment, therapeutic options in treatment-naive patients are mentioned as well.

Keywords: metastatic renal cell cancer, tyrosin-kinase inhibitors, immunotherapy, check-point inhibitors